The publication of this infographic was funded by Boehringer Ingelheim. This content is intended for US Healthcare Professionals. Please see full Prescribing Information for HERNEXEOS.
Oncology nurses support patients receiving targeted therapy by educating them on adverse event management. This infographic summarizes data from the Phase Ib Beamion LUNG-1 trial in previously treated patients with HER2-mutant NSCLC, helping nurses understand when diarrhea may occur and how it can be managed.
Topics covered:
- Time to onset after therapy initiation
- Severity and recurrence
- Frequency of treatment interruption and dose modification
- Use of supportive care
INDICATION
HERNEXEOS (zongertinib tablets) is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
